Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.5.1.1 - asparaginase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Asparagine and glutamine metabolism in chicks.
Adenocarcinoma
Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma.
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Adenocarcinoma of Lung
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
Sleeping Beauty Transposon-Mediated Asparaginase Gene Delivery by a Nanoparticle Platform.
Anaphylaxis
Amino acid degrading enzymes for cancer therapy.
Anaphylactic reaction to polyethylene glycol-conjugated asparaginase: premedication and desensitization may not be sufficient.
Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
Anaphylaxis and superior vena cava thrombus in a pediatric patient with acute lymphoblastic leukemia.
Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures.
Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.
Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli.
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences.
Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
[A technic for "desensitization" in case of asparaginase anaphylaxis during acute leukemia]
Antiphospholipid Syndrome
Thromboembolic complications related to indwelling central venous catheters in children.
Antithrombin III Deficiency
Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia.
Antithrombin III deficiency during asparaginase therapy.
Arthritis
Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase.
Aspartylglucosaminuria
Large-scale purification and preliminary x-ray diffraction studies of human aspartylglucosaminidase.
Asthenozoospermia
An in silico analysis of human sperm genes associated with asthenozoospermia and its implication in male infertility.
Ataxia Telangiectasia
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Blast Crisis
Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Treatment of Pegylated Asparaginase-Induced Hypertriglyceridemia with Continuous Intravenous Infusion of Insulin and Heparin: A Case Report.
Blood Coagulation Disorders
[Blood coagulation disorder due to asparaginase]
Bone Diseases, Developmental
Exceptional thermal stability of therapeutical enzymes entrapped in alumina sol-gel matrices.
Bone Diseases, Metabolic
Recent perspectives on the association between osteonecrosis and bone mineral density decline in childhood acute lymphoblastic leukemia.
Brain Diseases
Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase.
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
On the origin of EEG-slowing and encephalopathy during induction treatment of acute lymphoblastic leukemia.
Brain Diseases, Metabolic
Acute metabolic encephalopathy in two patients treated with asparaginase and ondasetron.
Breast Neoplasms
Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Burkitt Lymphoma
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.
[Physico-chemical properties of deamidase AG from Pseudomonas fluorescens AG possessing antitumor activity]
Carcinogenesis
ASRGL1 Correlates With Immune Cell Infiltration in Hepatocellular Carcinoma and Can Serve as a Prognostic Biomarker.
Genome-Wide Profiling of Cervical RNA-Binding Proteins Identifies Human Papillomavirus Regulation of RNASEH2A Expression by Viral E7 and E2F1.
Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.
Carcinoma
Asparaginase induces selective dose- and time-dependent cytotoxicity, apoptosis, and reduction of NF?B expression in oral cancer cells.
Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase.
Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase.
Carcinoma, Ductal
Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.
Carcinoma, Hepatocellular
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells.
ASRGL1 Correlates With Immune Cell Infiltration in Hepatocellular Carcinoma and Can Serve as a Prognostic Biomarker.
Carcinoma, Renal Cell
Human renal carcinoma: asparagine independence with asparaginase susceptibility in culture.
Chemical and Drug Induced Liver Injury
Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.
Natural Killer-Like T-Cell Lymphoma: A Rare Cause of Acute Liver Failure.
Choledocholithiasis
Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.
Cholelithiasis
Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.
Colonic Neoplasms
Glutaraldehyde-Mediated Synthesis of Asparaginase-Bound Maghemite Nanocomposites: Cytotoxicity against Human Colon Adenocarcinoma Cells.
Colorectal Neoplasms
Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy.
Free Asparagine or Die: Cancer Cells Require Proteasomal Protein Breakdown to Survive Asparagine Depletion.
Consciousness Disorders
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Dehydration
Industrially Applicable Strategies for Mitigating Acrylamide, Furan and 5-Hydroxymethylfurfural in Food.
Diabetes Mellitus, Type 2
Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation.
Disseminated Intravascular Coagulation
Clinical relevance of protein C.
Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan.
To be or not to be a case of heparin resistance.
[Heparin resistance and antithrombin deficiency]
Drug-Related Side Effects and Adverse Reactions
Asparaginase in acute lymphoblastic leukemia.
Duodenal Ulcer
Role of ?-glutamyl transpeptidase in the pathogenesis of Helicobacter pylori infection.
Dyslipidemias
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Encephalomyelitis
[ASPARAGINASE IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. 3. ASPARAGINASE IN THE LYMPH NODES AND SPLEEN IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN GUINEA PIGS.]
[Asparaginase in experimental allergic encephalomyelitis. IV. The relation of asparaginase of lymph nodes to asparaginase of the central nervous system in the process of development of experimental allergic encephalomyelitis in guinea pigs. The relationship between the histologic finding, the clinical picture and the asparaginase in the central nervous system]
Encephalomyelitis, Autoimmune, Experimental
ASPARAGINASE IN THE BRAIN OF GUINEA PIG IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS.
[ASPARAGINASE ACTIVITY IN THE NERVOUS SYSTEM IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. II.]
[ASPARAGINASE IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. 3. ASPARAGINASE IN THE LYMPH NODES AND SPLEEN IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN GUINEA PIGS.]
[Asparaginase in experimental allergic encephalomyelitis. IV. The relation of asparaginase of lymph nodes to asparaginase of the central nervous system in the process of development of experimental allergic encephalomyelitis in guinea pigs. The relationship between the histologic finding, the clinical picture and the asparaginase in the central nervous system]
Endometrial Neoplasms
Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study.
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Fatty Liver
Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.
L-Asparaginase-Induced Hepatotoxicity Treated Successfully With L-Carnitine and Vitamin B Infusion.
Gastritis
Role of ?-glutamyl transpeptidase in the pathogenesis of Helicobacter pylori infection.
Glioblastoma
Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase
Glioma
Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma.
Hematologic Neoplasms
Asparaginase in the treatment of non-ALL hematologic malignancies.
Hematologic malignancies and thrombosis.
Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia.
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.
Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy().
[Fatal central nervous system hemorrhage during acute lymphoblastic leukemia induction].
Hepatic Veno-Occlusive Disease
Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
[Hemostasis tests as markers of hepatic and endothelial toxicity in chemotherapy]
Hodgkin Disease
Non-classical secretion of a type I L-asparaginase in Bacillus subtilis.
Hypercholesterolemia
Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Hyperglycemia
Comment on: Glucose levels before the onset of asparaginase predicts transient hyperglycemia in children with acute lymphoblastic leukemia.
Diabetic ketoacidosis following PEG-asparaginase therapy
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Genetics of pleiotropic effects of dexamethasone.
Glucose Levels Before the Onset of Asparaginase Predicts Transient Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Homoharringtonine-induced hyperglycemia.
Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes.
Hyperglycemic Hyperosmolar State During Induction Chemotherapy for Acute Lymphoblastic Leukemia.
Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Incidence of Hyperglycemia during Induction of Remission Phase of Pediatric Acute Lymphoblastic Leukemia.
L-asparaginase related hyperglycemia.
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Reply to comment on: Glucose levels before the onset of asparaginase predicts transient hyperglycemia in children with acute lymphoblastic leukemia.
Safety and Efficacy of Metformin for Therapy-induced Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Hyperlipidemias
Asparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis.
Insulin infusion to treat severe hypertriglyceridemia associated with pegaspargase therapy: a case report.
L-Asparaginase and Steroids-associated Hypertriglyceridemia Successfully Treated With Plasmapheresis in a Child With Acute Lymphoblastic Leukemia.
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase.
[Transient hyperlipidemia secondary to treatment with asparaginase and prednisone]
Hypersensitivity
A 12-steps desensitization protocol for pediatric patients with hypersensitivity to pegylated asparaginase.
A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.
A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage.
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Adequate asparaginase is important to prevent central nervous system and testicular relapse of pediatric Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
Allergic reactions to asparaginase: Retrospective cohort study in pediatric patients with acute lymphoid leukemia.
Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions.
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Asparaginase allergies: it's all in the genes.
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.
Asparaginase entrapped in red blood cells: action and survival.
Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Asparaginase immune complexes induce Fc-?RIII-dependent hypersensitivity in naive mice.
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?
Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.
Clinical application of asparaginase activity levels following treatment with pegaspargase.
Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
Comparative pharmacokinetic studies of three asparaginase preparations.
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
CORRIGENDUM: Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity.
Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.
Effect of premedications in a murine model of asparaginase hypersensitivity.
Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase.
Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice.
Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.
Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia.
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.
HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.
HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.
HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia.
How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors Fc?RI and Fc?RIII.
Hypersensitivity reactions to chemotherapeutic drugs.
Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Is Erwinase Necessary for all Children With ALL and Allergic Reactions to E. coli Asparaginase?
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.
l-Asparaginase Production by Moderate Halophilic Bacteria Isolated from Maharloo Salt Lake.
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
Oncology update.
Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review.
Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability.
Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood ALL.
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458).
Production of a novel N-terminal PEGylated crisantaspase.
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene.
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Severe pegaspargase hypersensitivity reaction rates (grade ?3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.
The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia.
The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Tolerability and Efficacy of a 1-Bag Pegaspargase Densensitization Protocol in Pediatric Oncology Patients.
Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.
Tracking Silent Hypersensitivity Reactions to Asparaginase during Leukemia Therapy Using Single-Chip Indirect Plasmonic and Fluorescence Immunosensing.
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Two tagging single-nucleotide polymorphisms to capture HLA-DRB1*07:01-DQA1*02:01-DQB1*02:02 haplotype associated with asparaginase hypersensitivity.
Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.
Use of a protocol to minimize hypersensitivity reactions with asparaginase administration.
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
[Hypersensitivity reactions associated with the use of asparaginase in children with acute lymphoblastic leukemia].
[In Process Citation]
[New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase]
Hypersensitivity, Delayed
[Delayed hypersensitivity reaction caused by asparaginase]
Hypersensitivity, Immediate
Effect of premedications in a murine model of asparaginase hypersensitivity.
Hypertension
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.
Hypertriglyceridemia
A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis.
Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.
Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment.
Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia.
Drug-induced hypertriglyceridemia with and without pancreatitis.
Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Lipid Apheresis to Manage Severe Hypertriglyceridemia during Induction Therapy in a Child with Acute Lymphoblastic Leukemia.
Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.
Plasmapheresis in asparaginase-induced hypertriglyceridemia.
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase.
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity.
Treatment of Pegylated Asparaginase-Induced Hypertriglyceridemia with Continuous Intravenous Infusion of Insulin and Heparin: A Case Report.
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
[Severe hypertriglyceridemia secondary to asparaginase administered to adult patients: report of 2 cases and literature review].
Hypoalbuminemia
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
Hypoglycemia
Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
Hypokalemia
Genetics of pleiotropic effects of dexamethasone.
Hyponatremia
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Hypotension
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Infections
Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period.
Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service.
Asparagine deprivation mediated by Salmonella asparaginase causes suppression of activation-induced T cell metabolic reprogramming.
Contribution of Asparagine Catabolism to Salmonella Virulence.
Identification and validation of l-asparaginase as a potential metabolic target against Mycobacterium tuberculosis.
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Thromboembolic complications in pediatric hematologic malignancies.
Insulin Resistance
Association between body mass index and insulin resistance in survivors of pediatric acute lymphoblastic leukemia.
Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia.
Invasive Fungal Infections
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Ischemic Stroke
The Lectin Pathway in Thrombotic Conditions-A Systematic Review.
Lentivirus Infections
RNAi?mediated downregulation of asparaginase?like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa.
Leukemia
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia.
A sulfoximine-based inhibitor of human asparagine synthetase kills l-asparaginase-resistant leukemia cells.
Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature.
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells.
Analysis of long-term survival in acute leukemia and Burkitt's tumor--effects to be expected from intensive therapy and asparaginase.
Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
Antibody-producing cells: virus-induced alteration of response to antigen.
Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis.
Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Asparaginase immune complexes induce Fc-?RIII-dependent hypersensitivity in naive mice.
Asparaginase in the treatment of non-ALL hematologic malignancies.
Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.
Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy Against Brain Tumors.
Asparagine Synthetase Is Highly Expressed at Baseline in the Pancreas Through Heightened PERK Signaling.
ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.
Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany.
Cerebral Venous Sinus Thrombosis in Pediatric Cancer Patients: Long-term Neurological Outcomes.
Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).
Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.
Chromosomal pattern of asparaginase sensitive leukemia and its resistant variant.
Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.
Clinical trials of asparaginase in chemotherapy-resistant acute leukemias.
Cloning, expression, purification and characterisation of Erwinia carotovora L-asparaginase in Escherichia coli.
Comparison of crystalline and amorphous asparaginase in treatment of acute leukemia in children.
Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
Critical influence of an enzyme-elevating virus upon long-term remissions of mouse leukemia following asparaginase therapy.
Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia.
Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation.
Differentiation versus cytoreduction during remission induction in acute nonlymphoblastic leukemia treated with sequential high-dose ara-C and asparaginase.
Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Dose-related pharmacologic effects of high dose ara-C and its use in combination with asparaginase for the treatment of patients with acute non-lymphocytic leukemia.
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
Exceptional thermal stability of therapeutical enzymes entrapped in alumina sol-gel matrices.
Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy.
Free Asparagine or Die: Cancer Cells Require Proteasomal Protein Breakdown to Survive Asparagine Depletion.
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
Genetic markers for treatment-related pancreatitis in a cohort of Hispanic children with acute lymphoblastic leukemia.
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
High-dose Ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA.
High-throughput asparaginase activity assay in serum of children with leukemia.
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.
Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors Fc?RI and Fc?RIII.
Idiopathic Hyperammonemia That Developed During Initial Treatment With Steroid in a Patient With Newly Diagnosed Leukemia.
IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
Improvement of stability and enzymatic activity by site-directed mutagenesis of E. coli asparaginase II.
Influence of a benign virus upon mouse leukemia during asparaginase therapy.
Inhibitors of L-asparagine synthetase, in vitro.
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
L-asparaginase production review: bioprocess design and biochemical characteristics.
L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.
Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Natural and asparaginase induced death of L5178Y leukemia cells in vivo.
Peg-asparaginase for acute lymphoblastic leukemia.
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Preliminary results of the combination methotrexate-asparaginase in patients with acute non lymphoid leukemia.
Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Proteins from Erwinia asparaginase Erwinase(®) and E. coli asparaginase 2 MEDAC(®) for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Purification and characterization of glutaminase free asparaginase from Pseudomonas otitidis: Induce apoptosis in human leukemia MOLT-4 cells.
Rhabdomyolysis during myelosuppression in a patient with central nervous system leukemia: A case report.
Role of the LDH-elevating virus in leukemia therapy by asparaginase.
Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.
Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma.
Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma.
Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias.
Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia.
Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia.
Stability of L-asparaginase: an enzyme used in leukemia treatment.
Structural and functional insights into Erwinia carotovora L-asparaginase.
Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan.
Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients.
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias.
The hemostatic defect induced by treatment with asparaginase in leukemia.
The metabolic importance of the overlooked asparaginase II pathway.
Therapy of acute leukemia with drug combinations which include asparaginase.
Thromboembolic complications in pediatric hematologic malignancies.
Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia.
Tracking Silent Hypersensitivity Reactions to Asparaginase during Leukemia Therapy Using Single-Chip Indirect Plasmonic and Fluorescence Immunosensing.
Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
Use of asparaginase in conjunction with cytosine arabinoside in acute leukemia in children.
[A technic for "desensitization" in case of asparaginase anaphylaxis during acute leukemia]
[Adverse reactions to L-asparaginase in children with acute lymphatic leukemia]
[Antigenicity of E. coli asparaginase in enzyme therapy of leukemia]
[Asparaginase and acute leukemia]
[Asparaginase for acute leukemia resistant to various chemotherapies]
[Asparaginase in acute leukemia]
[Asparaginase in the treatment of acute leukemias (author's transl)]
[Asparaginase in the treatment of acute leukemias]
[Asparaginase, leukemia and cancer]
[Hemostasis tests as markers of hepatic and endothelial toxicity in chemotherapy]
[Results of the treatment of acute leukemias in children with asparaginase (critical study of 34 cases)]
[Sequential high-dose cytarabine therapy in combination with asparaginase in acute myeloid leukemia]
[Serum amino acids in acute leukemia of the adult during asparaginase therapy]
[The use of asparaginase preparations for the treatment of tumors and leukemia (review of the literature)]
[Therapy of leukemia in USA. 2. L asparaginase in leukemia]
Leukemia P388
Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part III--Combination experiments.
Murine and human leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.
Treatment of Pegylated Asparaginase-Induced Hypertriglyceridemia with Continuous Intravenous Infusion of Insulin and Heparin: A Case Report.
Leukemia, Myeloid
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.
Purification and Characterization of Glutaminase Free Asparaginase from Enterobacter cloacae: In-Vitro Evaluation of Cytotoxic Potential against Human Myeloid Leukemia HL-60 Cells.
Leukemia, Myeloid, Acute
Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.
Asparaginase unveils glutamine-addicted AML.
Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany.
Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
Differentiation versus cytoreduction during remission induction in acute nonlymphoblastic leukemia treated with sequential high-dose ara-C and asparaginase.
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group.
L-asparaginase production review: bioprocess design and biochemical characteristics.
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
The pharmacologic basis for the efficacy of high-dose Ara-C and sequential asparaginase in adult acute myelogenous leukemia.
Thrombosis and acute leukemia.
Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
[Sequential high-dose cytarabine therapy in combination with asparaginase in acute myeloid leukemia]
Leukemia, Prolymphocytic
Prolymphocytic leukemia. Response to asparaginase.
Leukemia, Promyelocytic, Acute
Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature.
Leukemia, T-Cell
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Leukocytosis
Current study of APL treatment in China.
Leukopenia
Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma--a rationale for tailored supportive care.
Profound leukopenia following asparaginase treatment in a patient with acute lymphoblastic leukaemia.
Liver Diseases
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Clinical relevance of protein C.
GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.
Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Liver Failure
Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period.
Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Liver Failure, Acute
Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.
Natural Killer-Like T-Cell Lymphoma: A Rare Cause of Acute Liver Failure.
Liver Neoplasms
On the liver asparaginase in the course of liver cancer production of rats fed on azo dye.
The landscape of cancer cell line metabolism.
Lymphatic Metastasis
Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study.
Lymphoma
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
An urchin-like helical polypeptide-asparaginase conjugate with mitigated immunogenicity.
Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
Anaplerotic reactions in tumour proliferation and apoptosis.
Antagonism of purified asparaginase from guinea pig serum toward lymphoma.
Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Asparaginase and MOPP treatment of dogs with lymphoma.
Asparaginase revisited.
Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer/T-cell lymphoma in vivo and in vitro.
Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas.
Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study.
Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride.
Clinical application of asparaginase activity levels following treatment with pegaspargase.
Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
Comparison of Native Escherichia Coli L-Asparaginase Versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP), in Extranodal NK/T Cell Lymphoma, Nasal Type (NTCL).
Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
E. coli-Derived L-Asparaginase Retains Enzymatic and Cytotoxic Activity In Vitro for Canine and Feline Lymphoma after Cold Storage.
Effect of asparaginase on cell membranes of sensitive and resistant mouse lymphoma cells.
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells.
Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
L-asparaginase kills lymphoma cells by apoptosis.
LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma.
LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.
Molecular cloning, structural modeling and production of recombinant Aspergillus terreusl. asparaginase in Escherichia coli.
Natural Killer-Like T-Cell Lymphoma: A Rare Cause of Acute Liver Failure.
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma.
Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma.
Structure-Function Relationships and Clinical Applications of L-Asparaginases.
Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy.
Ultrasound-propelled nanowire motors enhance asparaginase enzymatic activity against cancer cells.
[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases]
[Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma].
[Isolation and properties of a homogeneous L-asparaginase preparation from Pseudomonas fluorescens AG]
[Preparation of repeatedly and effectively usable L-asparaginase by a chemical modification]
Lymphoma, B-Cell
[Effect of Asparaginase on Diffuse Large B-Cell Lymphoma Cell Apoptosis and Its Related Mechanism].
Lymphoma, Large B-Cell, Diffuse
Biochemical and pathophysiological characterization of Helicobacter pylori asparaginase.
[Effect of Asparaginase on Diffuse Large B-Cell Lymphoma Cell Apoptosis and Its Related Mechanism].
Lymphoma, Mantle-Cell
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
Lymphoma, Non-Hodgkin
Amino acids of the 6C3HED lymphosarcoma following treatment with asparaginase.
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Cerebral Venous Sinus Thrombosis in Pediatric Cancer Patients: Long-term Neurological Outcomes.
Changes in ribonuclease activities in P1798 lymphosarcoma after asparaginase treatment.
Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Saccharomyces cerevisiae asparaginase II, a potential antileukemic drug: Purification and characterization of the enzyme expressed in Pichia pastoris.
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
The properties and large-scale production of L-asparaginase from citrobacter.
TRANSIENT HYPERAMMONEMIA DUE TO L -ASPARAGINASE THERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR NON-HODGKIN LYMPHOMA.
Use of L-asparaginase in childhood ALL.
[Adverse reactions associated with the use of L-asparaginase during therapy of patients with nB non-Hodgkin's lymphoma. Report of the Polish Paediatric LeuKaemia/Lymphoma Study Group]
Lymphoma, T-Cell
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.
Lymphoproliferative Disorders
Molecular cloning, structural modeling and production of recombinant Aspergillus terreusl. asparaginase in Escherichia coli.
Medulloblastoma
Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma.
Meningitis
[Allergic meningitis due to asparaginase sensitivity during acute lymphoblastic leukemia]
[Leukemic meningitis, purulent meningitis, allergic meningitis due to asparaginase sensitization: successive episodes in the course of acute lymphoblastic leukemia]
Mesenteric Ischemia
Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase.
Mouth Neoplasms
Asparaginase induces selective dose- and time-dependent cytotoxicity, apoptosis, and reduction of NF?B expression in oral cancer cells.
Myelodysplastic Syndromes
Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany.
Neoplasm Metastasis
Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study.
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Neoplasm, Residual
High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Inherited GATA3 variant associated with positive minimal residual disease in childhood B-cell acute lymphoblastic leukemia via asparaginase resistance.
Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]
Neoplasms
A newly identified glutaminase-free ?-asparaginase (?-ASPG86) from a marine bacterium Mesoflavibacter zeaxanthinifaciens.
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model.
Age modulates liver responses to asparaginase-induced amino acid stress in mice.
Amino acid metabolism as a therapeutic target in cancer: a review.
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Antitumor activity and ability to prevent acrylamide formation in fried foods of asparaginase from soybean root nodules.
As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid.
Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.
Asparaginase induces selective dose- and time-dependent cytotoxicity, apoptosis, and reduction of NF?B expression in oral cancer cells.
Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth.
Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase.
Asparagine synthetase: Function, structure, and role in disease.
Asparagine Synthetase: Regulation by Cell Stress and Involvement in Tumor Biology.
Aspartate is an endogenous metabolic limitation for tumour growth.
Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase
Bacillus sonorensis L. Asparaginase: Cloning, Expression in E. coli and Characterization.
BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2.
Carbon nanoparticle from a natural source fabricated for folate receptor targeting, imaging and drug delivery application in A549 lung cancer cells.
Characterisation and molecular dynamic simulations of J15 asparaginase from Photobacterium sp. strain J15.
Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters.
Clinical relevance of protein C.
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
Crystal structure of active site mutant of antileukemic l-asparaginase reveals conserved zinc-binding site.
Deprivation of asparagine triggers cytoprotective autophagy in laryngeal squamous cell carcinoma.
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
Discovery of why acute lymphoblastic leukaemia cells are killed by asparaginase: Adventures of a young post-doctoral student, Bertha K Madras.
Drug-induced pancreatitis.
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
Effects of A6E Mutation on Protein Expression and Supramolecular Assembly of Yeast Asparagine Synthetase.
Effects of asparagine synthetase inhibitors on asparaginase resistant tumors.
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Enzymes in cancer. Asparaginase from chicken liver.
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101].
Free Asparagine or Die: Cancer Cells Require Proteasomal Protein Breakdown to Survive Asparagine Depletion.
Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma.
HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.
How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia.
Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes.
Immunity and asparaginase suppression of tumor growth.
Immunoassay of enzymes--an overview.
Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice.
Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group.
Improvement of stability and enzymatic activity by site-directed mutagenesis of E. coli asparaginase II.
Improving the Treatment of Acute Lymphoblastic Leukemia.
In silico identification and characterization of antineoplastic asparaginase enzyme from endophytic bacteria.
Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.
Inhibitors of L-asparagine synthetase, in vitro.
Insights into the microbial L-asparaginases: from production to practical applications.
Isolation, purification, characterisation and application of L-ASNase (L-ASNase): A review.
L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors.
L-asparaginase production review: bioprocess design and biochemical characteristics.
L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.
l-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Molecular Cloning, Biochemical Characterization, and Antitumor Properties of a Novel L-Asparaginase from Synechococcus elongatus PCC6803.
Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
Non-classical secretion of a type I L-asparaginase in Bacillus subtilis.
Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer.
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Production and structural modeling of a novel asparaginase in Yarrowia lipolytica.
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Prophylactic use of octreotide for asparaginase-induced acute pancreatitis.
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Purification and Characterization of Glutaminase Free Asparaginase from Enterobacter cloacae: In-Vitro Evaluation of Cytotoxic Potential against Human Myeloid Leukemia HL-60 Cells.
Purification and Some Biological Properties of Asparaginase from Azotobacter vinelandii.
Recent developments in l-asparaginase discovery and its potential as anticancer agent.
Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
RNAi?mediated downregulation of asparaginase?like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa.
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Tackling Critical Catalytic Residues in Helicobacter pylori L-Asparaginase.
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
The curability of advanced cancers with chemotherapy.
The effect on macromolecular synthesis of amino acid deprivation of hamster kidney cells.
The preparation of insoluble, matrix-supported derivatives of asparaginase for use in cancer therapy.
The role of asparagine synthetase on nutrient metabolism in pancreatic disease.
The role of autophagy in asparaginase-induced immune suppression of macrophages.
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes.
Therapy of acute lymphoblastic leukaemia in childhood: effects on the nervous system.
Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study.
Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Tumour regression with liposome-entrapped asparaginase: some immunological advantages.
Two tagging single-nucleotide polymorphisms to capture HLA-DRB1*07:01-DQA1*02:01-DQB1*02:02 haplotype associated with asparaginase hypersensitivity.
Ultrasound-propelled nanowire motors enhance asparaginase enzymatic activity against cancer cells.
Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia.
[Activity of asparaginase and glutaminase of chickens with experimental sarcomatosis]
[Antitumor activity of L-asparaginase from Erwinia carotovora from against different leukemic and solid tumours cell lines].
[Asparaginase, leukemia and cancer]
[Monoaminodicarboxylic acids and their amides in tissues during regressive tumor growth]
[Physico-chemical properties of deamidase AG from Pseudomonas fluorescens AG possessing antitumor activity]
[Severe acute pancreatitis in children receiving asparaginase: multicenter retrospective study]
[Study of glutaminase and asparaginase activities in normal tissues and malignant tumors]
[The enzyme asparaginase as a possible cytostaticum in therapy of malignant tumor in the jaw face region]
[The use of asparaginase preparations for the treatment of tumors and leukemia (review of the literature)]
Neoplastic Processes
Antibody-producing cells: virus-induced alteration of response to antigen.
Neuritis
Asparaginase in peripheral nerves of the guinea pig in Wallerian degeneration and experimental allergic neuritis.
Neuritis, Autoimmune, Experimental
Asparaginase in peripheral nerves of the guinea pig in Wallerian degeneration and experimental allergic neuritis.
Obesity
Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia.
Obesity Challenges the Hepatoprotective Function of the Integrated Stress Response to Asparaginase Exposure in Mice.
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Osteonecrosis
A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday.
Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.
Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model.
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Genetics of pleiotropic effects of dexamethasone.
Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia.
Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.
Recent perspectives on the association between osteonecrosis and bone mineral density decline in childhood acute lymphoblastic leukemia.
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Overweight
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Pancreatic Neoplasms
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101].
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Pancreatic Pseudocyst
Pancreatic pseudocyst in an adult patient after treatment with pegylated asparaginase.
Pancreatitis
Acute Pancreatitis Associated With Cytarabine During the Treatment of Pediatric Acute Myeloid Leukemia.
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.
Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Asparagine Synthetase Is Highly Expressed at Baseline in the Pancreas Through Heightened PERK Signaling.
Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.
Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemia.
Drug-induced pancreatitis.
Drug-induced pancreatitis: an update.
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
General control nonderepressible kinase 2 (GCN2) deletion predisposes to asparaginase-associated pancreatitis in mice.
Genetic markers for treatment-related pancreatitis in a cohort of Hispanic children with acute lymphoblastic leukemia.
Iatrogenic pancreatitis. A fatal complication in the induction therapy for acute lymphocytic leukemia.
Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion.
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia.
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Pancreatitis in a child with acute lymphoblastic leukemia after Erwinia asparaginase: Evaluation of ultrasonography and computerized tomography as diagnostic tools.
Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit.
Plasmapheresis in asparaginase-induced hypertriglyceridemia.
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Predicting asparaginase-associated pancreatitis.
Prophylactic use of octreotide for asparaginase-induced acute pancreatitis.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Risk Factors for Asparaginase-associated Pancreatitis: A Systematic Review.
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia.
Somatostatin therapy in L-asparaginase-induced pancreatitis.
Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report.
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases]
[Iconographic rubric. A case of acute pancreatitis caused by asparaginase]
[In Process Citation]
[Severe acute pancreatitis in children receiving asparaginase: multicenter retrospective study]
Pancreatitis, Acute Hemorrhagic
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
[Acute hemorrhagic pancreatitis caused by asparaginase. A case in a child with a favorable course]
[Acute severe steatosis following an acute necrotic, hemorrhagic pancreatitis after treatment with asparaginase]
Pancreatitis, Acute Necrotizing
[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases]
Parasitemia
Knockdown of asparagine synthetase A renders Trypanosoma brucei auxotrophic to asparagine.
Paresis
Cerebral Sinus Venous Thrombosis due to Asparaginase Therapy.
Peripheral Nervous System Diseases
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia.
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Phenylketonurias
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Posterior Leukoencephalopathy Syndrome
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis.
A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.
A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.
A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients.
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia.
Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature.
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
Adequate asparaginase is important to prevent central nervous system and testicular relapse of pediatric Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol.
Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice.
Albumin/asparaginase capsules prepared by ultrasound to retain ammonia.
Allergic reactions to asparaginase: Retrospective cohort study in pediatric patients with acute lymphoid leukemia.
Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells.
Ammonia levels should not be used as a surrogate marker of levels of asparaginase activity in acute lymphoblastic leukemia patients.
An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Anaphylaxis and superior vena cava thrombus in a pediatric patient with acute lymphoblastic leukemia.
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.
Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Application of repeated aspartate tags to improving extracellular production of Escherichia coli L-asparaginase isozyme II.
Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.
Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults.
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.
Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.
Asparaginase in acute lymphoblastic leukemia.
Asparaginase in combination chemotherapy for remission induction of childhood acute lymphocytic leukemia.
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.
Asparaginase inhibits the lectin pathway of complement activation.
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.
Asparaginase products in upfront acute lymphoblastic leukemia therapy: Value, location, and style.
Asparaginase revisited.
Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Asparaginase use for the treatment of acute lymphoblastic leukemia.
Asparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis.
Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives.
Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment.
Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment.
Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with PEG-Asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
Asparagine synthetase: Function, structure, and role in disease.
Asparagine Synthetase: Regulation by Cell Stress and Involvement in Tumor Biology.
Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL.
ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.
Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy.
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.
Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
Cerebral Sinus Venous Thrombosis due to Asparaginase Therapy.
Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation.
Characterization of a recombinant glutaminase-free L-asparaginase (ansA3) enzyme with high catalytic activity from Bacillus licheniformis.
Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.
Clinical application of asparaginase activity levels following treatment with pegaspargase.
Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study.
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
Cloning, expression and characterization of L-asparaginase from Pseudomonas fluorescens for large scale production in E. coli BL21.
Cloning, expression and characterization of l-asparaginase from Withania somnifera L. for large scale production.
Comment on: Glucose levels before the onset of asparaginase predicts transient hyperglycemia in children with acute lymphoblastic leukemia.
Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia.
Complete blood count using VCS (volume, conductivity, light scatter) technology is affected by hyperlipidemia in a child with acute leukemia.
Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy.
Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemia.
Construction of expression systems for Escherichia coli asparaginase II and two-step purification of the recombinant enzyme from periplasmic extracts.
Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.
Crystal structure of active site mutant of antileukemic l-asparaginase reveals conserved zinc-binding site.
Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy.
Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase.
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
Diabetic ketoacidosis following PEG-asparaginase therapy
Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.
Dose Intensification of Methotrexate and Cytarabine During Intensified Continuation Chemotherapy for High-risk B-Precursor Acute Lymphoblastic Leukemia: POG 9406: A Report From the Children's Oncology Group.
Dural sinus thrombosis in children with acute lymphoblastic leukemia.
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
Effects of A6E Mutation on Protein Expression and Supramolecular Assembly of Yeast Asparagine Synthetase.
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.
Engineering Cell-Free Protein Synthesis for High-Yield Production and Human Serum Activity Assessment of Asparaginase: Toward On-Demand Treatment of Acute Lymphoblastic Leukemia.
Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248.
Enhanced catalysis of l-asparaginase from Bacillus licheniformis by a rational redesign.
Enzymes in Metabolic Anticancer Therapy.
Erroneous Exchange of Asparaginase Forms in the Treatment of Acute Lymphoblastic Leukemia.
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Establishment and characterization of a novel childhood acute lymphoblastic leukemia cell line, HXEX-ALL1, with chromosome 9p and 17p deletions.
Establishment of asparaginase- and guinea pig complement-resistant subline of murine lymphoblastic leukemia L5178y cells.
Evaluation of Antineoplastic Activity of Extracellular Asparaginase Produced by Isolated Bacillus circulans.
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Excessive toxicities of pegylated asparaginase in pediatric acute lymphoblastic leukemia patients with high body surface area: A call for action.
Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
Expression and characterization of recombinant l-asparaginase from Pseudomonas fluorescens.
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.
Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.
Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.
Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.
Glucose Levels Before the Onset of Asparaginase Predicts Transient Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.
High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?
High-throughput asparaginase activity assay in serum of children with leukemia.
Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase.
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.
HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia.
How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia.
How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Hyperammonemia secondary to asparaginase: A case series.
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.
Iatrogenic pancreatitis. A fatal complication in the induction therapy for acute lymphocytic leukemia.
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.
IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Improved treatment results of non-Hodgkin's lymphoma in children: a report from the Children's Cancer and Leukemia Study Group of Japan.
Improving the Treatment of Acute Lymphoblastic Leukemia.
Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.
Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.
Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia.
Inherited GATA3 variant associated with positive minimal residual disease in childhood B-cell acute lymphoblastic leukemia via asparaginase resistance.
Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia.
Insulin infusion to treat severe hypertriglyceridemia associated with pegaspargase therapy: a case report.
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia.
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Interaction between Gallic acid and Asparaginase to potentiate anti-proliferative effect on lymphoblastic leukemia cell line.
Interaction of alpha 2-macroglobulin with L-asparaginase.
Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
IV Administration of Erwinia-Derived Asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia: Single-Centre Case Series.
L-asparaginase production review: bioprocess design and biochemical characteristics.
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
L-Asparaginase-Induced Hepatotoxicity Treated Successfully With L-Carnitine and Vitamin B Infusion.
L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
L-carnitine and Vitamin B Complex for PEG-L-asparaginase-Induced Hepatotoxicity.
Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature.
Lipid Apheresis to Manage Severe Hypertriglyceridemia during Induction Therapy in a Child with Acute Lymphoblastic Leukemia.
Liposomal Daunorubicin (Daunoxome) and Polyethylated Glycol Conjugated Asparaginase (PEG-ASPA) in Children with Relapsed and Refractory Acute Lymphoblastic Leukemia Treated on Compassionate Basis.
Low-dosage asparaginase treatment of childhood acute lymphocytic leukemia.
Low-molecular-weight heparin in pediatric patients.
Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood.
Microbial production, molecular modification, and practical application of l-Asparaginase: A review.
Microchip CE-LIF method for the hydrolysis of L-glutamine by using L-asparaginase enzyme reactor based on gold nanoparticle.
Micronucleus incidence and their chromosomal origin related to therapy in acute lymphoblastic leukemia (ALL) patients: detection by micronucleus and FISH techniques.
Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia.
Molecular cloning, structural modeling and production of recombinant Aspergillus terreusl. asparaginase in Escherichia coli.
Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries.
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.
Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: preliminary data.
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
Non-classical secretion of a type I L-asparaginase in Bacillus subtilis.
Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
Oncology update.
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Optimization of culture conditions and bench-scale production of anticancer enzyme L-asparaginase by submerged fermentation from Aspergillus terreus CCT 7693.
Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Pain intensity and bioavailability of intramuscular asparaginase and a local anesthetic: a double-blinded study.
Pancreatitis in a child with acute lymphoblastic leukemia after Erwinia asparaginase: Evaluation of ultrasonography and computerized tomography as diagnostic tools.
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Peg-asparaginase for acute lymphoblastic leukemia.
PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma.
PEG-asparaginase induced severe hypertriglyceridemia.
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia (†).
Pegylated asparaginase in front-line treatment of children with acute lymphoblastic leukemia.
PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability.
Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase.
Personalized nanomedicine: a rapid, sensitive, and selective UV-vis spectrophotometry method for the quantification of nanostructured PEG-asparaginase activity in children's plasma.
Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment.
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.
Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial.
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Plasmapheresis in asparaginase-induced hypertriglyceridemia.
Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood ALL.
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458).
Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.
Population pharmacokinetics of native Escherichia coli asparaginase.
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.
Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.
Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Production of a novel N-terminal PEGylated crisantaspase.
Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients.
Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.
Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Proteins from Erwinia asparaginase Erwinase(®) and E. coli asparaginase 2 MEDAC(®) for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Purification and characterization of glutaminase free asparaginase from Pseudomonas otitidis: Induce apoptosis in human leukemia MOLT-4 cells.
Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia.
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.
Reactions related to asparaginase infusion in a 10-year retrospective cohort.
Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood.
Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: improved results and revised prognostic criteria.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Reply to comment on: Glucose levels before the onset of asparaginase predicts transient hyperglycemia in children with acute lymphoblastic leukemia.
Rhizobium etli asparaginase II: An alternative for acute lymphoblastic leukemia (ALL) treatment.
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Safety and Efficacy of Metformin for Therapy-induced Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study.
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia.
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
Space for Calaspargase? A New Asparaginase for Acute Lymphoblastic Leukemia.
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase.
Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management.
Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients.
Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?
Tackling Critical Catalytic Residues in Helicobacter pylori L-Asparaginase.
Targeting the Proline-Glutamine-Asparagine-Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy.
The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
The eukaryotic initiation factor 2 (eIF2) kinase GCN2 protects against hepatotoxicity during asparaginase treatment.
The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia.
The impact of prophylactic fresh frozen plasma and cryoprecipitate on the incidence of CNS thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase.
The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
The long-term impact of in vitro drug sensitivity testing on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Therapeutic drug monitoring of asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-asparaginase in the AIEOP-BFM ALL 2009 study.
Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift.
Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Thrombosis and acute leukemia.
Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Thyroid function is not affected by second exposure to erwinia asparaginase for childhood acute lymphoblastic leukemia.
Tracking Silent Hypersensitivity Reactions to Asparaginase during Leukemia Therapy Using Single-Chip Indirect Plasmonic and Fluorescence Immunosensing.
TRANSIENT HYPERAMMONEMIA DUE TO L -ASPARAGINASE THERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR NON-HODGKIN LYMPHOMA.
Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity.
Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase.
Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?: Results from a prospective randomized trial.
Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study.
Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia.
Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.
Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.
Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.
VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia.
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases]
[Allergic meningitis due to asparaginase sensitivity during acute lymphoblastic leukemia]
[COALL-80 therapy in the management of acute lymphoblastic leukemia in childhood--an interim report]
[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]
[Effect of E coli or Erwinia asparaginase and corticotherapy on fibrinogen concentration in induction of acute lymphoblastic leukemia in children]
[Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
[Fatal central nervous system hemorrhage during acute lymphoblastic leukemia induction].
[Hypersensitivity reactions associated with the use of asparaginase in children with acute lymphoblastic leukemia].
[L-asparaginase study results (phase II of the clinical trials)]
[Leukemic meningitis, purulent meningitis, allergic meningitis due to asparaginase sensitization: successive episodes in the course of acute lymphoblastic leukemia]
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]
[New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase]
[Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia]
[Treatment of acute lymphoid leukemia in adults]
[Venous thrombosis of cranial sinuses in asparaginase therapy. A case report]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL.
Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL.
Recent Advances in the Management of Acute Lymphoblastic Leukaemia.
Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL).
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Prostatic Neoplasms
Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer.
Pulmonary Disease, Chronic Obstructive
Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers.
Pulmonary Embolism
Haemostatic alterations induced by treatment with asparaginases and clinical consequences.
The Lectin Pathway in Thrombotic Conditions-A Systematic Review.
Respiratory Insufficiency
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Retinal Degeneration
A missense mutation in ASRGL1 is involved in causing autosomal recessive retinal degeneration.
Retinal Dystrophies
A missense mutation in ASRGL1 is involved in causing autosomal recessive retinal degeneration.
Sarcoma
Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma.
[Monoaminodicarboxylic acids and their amides in tissues during regressive tumor growth]
Seizures
Cerebral Sinus Venous Thrombosis due to Asparaginase Therapy.
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Sepsis
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
Sinus Thrombosis, Intracranial
Dural sinus thrombosis in children with acute lymphoblastic leukemia.
Inherited thrombophilic factors do not increase central venous catheter blockage in children with malignancy.
Starvation
Asparagine metabolism and nitrogen distribution during protein degradation in sugar-starved maize root tips.
Characterization of two forms of asparaginase in Saccharomyces cerevisiae.
Insights into the microbial L-asparaginases: from production to practical applications.
L-asparaginase II of saccharomyces cerevisiae. Activity profile during growth using an ure2 mutant P40-3C and a P40-3C + URE2p strain.
L-Asparaginase of Saccharomyces cerevisiae: an extracellular Enzyme.
The effect on macromolecular synthesis of amino acid deprivation of hamster kidney cells.
The eIF2 kinase GCN2 is essential for the murine immune system to adapt to amino acid deprivation by asparaginase.
Transport and metabolic effects of alpha-aminoisobutyric acid in Saccharomyces cerevisiae.
[Asparaginase and adenosine deaminase activity in the liver tissue of rats parenterally administered nitrogenous preparations in protein starvation]
Stomach Neoplasms
Role of ?-glutamyl transpeptidase in the pathogenesis of Helicobacter pylori infection.
Stomach Ulcer
Role of ?-glutamyl transpeptidase in the pathogenesis of Helicobacter pylori infection.
Stroke
The Lectin Pathway in Thrombotic Conditions-A Systematic Review.
Superior Vena Cava Syndrome
Anaphylaxis and superior vena cava thrombus in a pediatric patient with acute lymphoblastic leukemia.
Tetanus
Asparaginase Display of Human Cholesteryl Ester Transfer Protein (CETP) B Cell Epitopes for Inducing High Titers of Anti-CETP Antibodies In Vivo.
Thrombocytopenia
Thromboembolic complications related to indwelling central venous catheters in children.
Thrombocytosis
Asparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis.
Thromboembolism
Central venous line-related thromboembolism is common in children with non-high risk acute lymphoblastic leukaemia.
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Management of thrombotic complications in acute lymphoblastic leukemia.
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
The development of thromboembolism may increase the risk of osteonecrosis in children with acute lymphoblastic leukemia.
Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.
Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.
Thrombophilia
Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer--a prospective study.
Thrombosis and acute lymphoblastic leukaemia.
Thrombosis
A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.
An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis.
Cerebral sinovenous thrombosis during asparaginase treatment. Case 3.
Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase.
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Genetics of pleiotropic effects of dexamethasone.
Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion.
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
The impact of prophylactic fresh frozen plasma and cryoprecipitate on the incidence of CNS thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase.
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH.
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.
Thrombosis and acute leukemia.
Thrombosis and acute lymphoblastic leukaemia.
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.
Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]
[Thrombosis in children with acute lymphoblastic leukemia treated with the COALL protocol]
[Venous thrombosis of cranial sinuses in asparaginase therapy. A case report]
Toxemia
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Triple Negative Breast Neoplasms
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Tuberculosis
Leishmania donovani asparaginase variants exhibit cytosolic localization.
Mycobacterium tuberculosis exploits asparagine to assimilate nitrogen and resist acid stress during infection.
Tuberous Sclerosis
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Urea Cycle Disorders, Inborn
Pegylated asparaginase as cause of fatal hyperammonemia in patients with latent urea cycle disorder.
Urticaria
Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Uterine Cervical Neoplasms
RNAi?mediated downregulation of asparaginase?like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa.
Venous Thromboembolism
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Hematologic malignancies and thrombosis.
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Venous Thrombosis
A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients.
Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model.
Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
Cerebral Sinus Venous Thrombosis due to Asparaginase Therapy.
Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase.
Haemostatic alterations induced by treatment with asparaginases and clinical consequences.
Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management.
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH.
Thrombosis in children with hematologic malignancies.
Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
[Venous thrombosis of cranial sinuses in asparaginase therapy. A case report]